3 results
Approved WMOCompleted
To assess the safety, tolerability and the effects of treatment on ocular outcomes following a single intravitreal administration of ESBA1008 compared to Lucentis in patients with exudative AMD
Approved WMOCompleted
Primary:• To demonstrate that RTH258 6 mg is not inferior to aflibercept 2 mg with respect to the change in best-corrected visual acuity (BCVA) from Baseline to Week 48Secondary:• To demonstrate that RTH258 6 mg is not inferior to aflibercept 2 mg…
Approved WMOCompleted
Primary objectives:* To assess telmisartan target (i.e. receptor) specific binding in vivo* To assess receptor occupancy of telmisartan in vivo* To determine optimal scanning time in vivoSecondary objective:* To explore the effect of telmisartan on…